Stage III Colon Cancer AJCC V8

general

Stage IIIA includes: (T1-T2, N1/N1c, M0); (T1, N2a, M0). T1: Tumor invades the submucosa (through the muscularis mucosa but not into the muscularis propria). T2: Tumor invades the muscularis propria. N1: One to three regional lymph nodes are positive (tumor in lymph nodes measuring 0.2 mm or more), or any number of tumor deposits are present and all identifiable lymph nodes are negative. N1c: No regional lymph nodes are positive, but there are tumor deposits in the subserosa, mesentery, or nonpe

72

Centers

172

Active Trials

Cancer Funding

Specific Cancer Types(1)

NameCenters
Stage IIIC Colon Cancer AJCC v838

Top Centers for Stage III Colon Cancer AJCC V8(72)

Ranked by research excellence score (trials · grants · publications). Methodology →

#CenterScore
1
High-Volume Research Center
72.9
2
High-Volume Research Center
72.3
3
NCI Comprehensive
Active Research Program
69.8
4
NCI Comprehensive
Active Research Program
69.8
569.8
6
NCI Comprehensive
Active Research Program
69.8
7
NCI Clinical
Active Research Program
69.8
8
NCI Clinical
Active Research Program
69.8
9
Active Research Program
69.8
10
NCI Comprehensive
Active Research Program
64.8
11
NCI Comprehensive
Active Research Program
64.8
12
NCI Comprehensive
Active Research Program
64.8
13
NCI Comprehensive
Active Research Program
64.8
14
NCI Comprehensive
Active Research Program
64.8
15
NCI Comprehensive
Active Research Program
64.8
16
NCI Comprehensive
Active Research Program
64.8
17
NCI Comprehensive
Active Research Program
64.8
18
Active Research Program
64.8
19
NCI Comprehensive
Active Research Program
55.1
20
NCI Comprehensive
Active Research Program
55.1
21
NCI Comprehensive
Active Research Program
55.1
22
NCI Comprehensive
Active Research Program
55.1
23
NCI Comprehensive
Active Research Program
55.1
24
Masonic Cancer CenterMinneapolis, MN
NCI Comprehensive
Active Research Program
55.1
25
NCI Comprehensive
Active Research Program
55.1
26
NCI Comprehensive
Active Research Program
55.1
27
NCI Comprehensive
Active Research Program
55.1
28
NCI Comprehensive
Active Research Program
55.1
29
Active Research Program
55.1
30
NCI Clinical
Active Research Program
55.1
31
NCI Comprehensive
Active Research Program
55.1
32
Rutgers Cancer InstituteNew Brunswick, NJ
NCI Comprehensive
Active Research Program
55.1
33
Active Research Program
55.1
3455.1
35
Active Research Program
55.1
36
Active Research Program
55.1
37
Active Research Program
55.1
38
Active Research Program
55.1
3955.1
40
Active Research Program
55.1
41
NCI Comprehensive
Active Research Program
38.5
42
NCI Comprehensive
Active Research Program
38.5
43
NCI Comprehensive
Active Research Program
38.5
44
NCI Comprehensive
Active Research Program
38.5
45
NCI Comprehensive
Active Research Program
38.5
46
NCI Comprehensive
Active Research Program
38.5
47
NCI Comprehensive
Active Research Program
38.5
48
NCI Comprehensive
Active Research Program
38.5
49
NCI Comprehensive
Active Research Program
38.5
50
NCI Comprehensive
Active Research Program
38.5
51
NCI Comprehensive
Active Research Program
38.5
52
NCI Comprehensive
Active Research Program
38.5
53
NCI Clinical
Active Research Program
38.5
54
NCI Comprehensive
Active Research Program
38.5
55
NCI Comprehensive
Active Research Program
38.5
56
Active Research Program
38.5
57
Cedars-Sinai CancerLos Angeles, CA
Active Research Program
38.5
58
NCI Comprehensive
Active Research Program
38.5
59
NCI Comprehensive
Active Research Program
38.5
60
NCI Comprehensive
Active Research Program
38.5
61
NCI Comprehensive
Active Research Program
38.5
62
Active Research Program
38.5
63
Fox Chase Cancer CenterPhiladelphia, PA
NCI Comprehensive
Active Research Program
38.5
64
NCI Comprehensive
Active Research Program
38.5
65
Active Research Program
38.5
66
Active Research Program
38.5
67
NCI Basic_laboratory
Active Research Program
38.5
68
Active Research Program
38.5
69
Active Research Program
38.5
70
Active Research Program
38.5
71
Active Research Program
38.5
72
NCI Comprehensive
28.5

Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →